GILD vs INSM vs ALNY Stock Comparison

Gilead Sciences, Insmed and Alnylam Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$207.56B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
4 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$26.90B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

9 decided of 12

Gilead Sciences leads on 4 of the 12 questions below (Gilead Sciences 4, Alnylam Pharmaceuticals 3, Insmed 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGILDINSMALNYLeader
Larger companyMarket capitalisation $207.56B $26.90B $21.33B GILD
Cheaper on earningsLower P/E, profitable companies only -53.7x -44.4x 8.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 8.6x –
Faster revenue growthRevenue growth, trailing twelve months +6.5% +240.0% +60.8% INSM
More profitableNet margin, trailing twelve months -12.5% -39.9% 52.8% ALNY
Better return on capitalReturn on invested capital -6.1% -41.1% — GILD
Less leveragedLower net debt / EBITDA 43.8x 1.1x -3.1x ALNY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +34.2% -36.6% -63.6% GILD
Better 5-year returnAnnualised price return, 5 years +20.0%/yr +30.6%/yr -0.7%/yr INSM
Less volatileAnnualised volatility, 1 year 27.5% 62.2% 59.1% GILD
Higher overall scoreMean of the five percentile scores vs peers 61/100 66/100 81/100 ALNY

Percentile Scorecard

GILDINSMALNY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGILDINSMALNY
Valuation 89 #71 of 660 70 #201 of 660 91 #61 of 660
Growth 34 #408 of 619 85 #91 of 619 99 #10 of 619
Profitability 85 #91 of 595 69 #186 of 595 91 #55 of 595
Financial Health 22 #530 of 683 37 #428 of 683 61 #269 of 683
Shareholder Returns 75 #116 of 459 67 #153 of 459 66 #156 of 459
Overall 61 66 81
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ALNY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGILDINSMALNYSPY
1 month +9.5%+23.9%-26.5% -2.0%
3 months +21.5%-2.1%-27.8% -2.8%
6 months +29.7%+11.0%-42.5% +2.0%
Year to date +36.9%-30.4%-58.5% +10.6%
1 year +34.2%-36.6%-63.6% +12.2%
3 years +124.9%+393.7%-2.9% +68.1%
3 years, per year +31.1%+70.3%-1.0% +18.9%
5 years +149.1%+280.3%-3.4% +61.4%
5 years, per year +20.0%+30.6%-0.7% +10.1%
10 years +119.9%+738.5%+254.6% +248.5%
10 years, per year +8.2%+23.7%+13.5% +13.3%

Risk

MeasureGILDINSMALNYSPY
Volatility, 1Y 27.5%62.2%59.1% 13.6%
Downside volatility, 1Y 24.0%61.0%74.1% 13.9%
Beta vs S&P 500, 1Y 0.390.550.50 1.00
Return / volatility, 1Y 1.25-0.59-1.08 0.90
Max drawdown, 5Y -29.4%-56.5%-69.1% -25.4%
From 52-week high -3.7%-42.7%-65.1% -3.2%
52-week high $174.48$211.41$473.29 $779.14
52-week low $118.30$91.88$151.64 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGILDINSMALNY
P/E now vs peer median -54.0xmedian 17.0x -43.8xmedian 17.0x 8.3xmedian 17.0x
P/S now vs peer median 6.7xmedian 8.4x 17.5xmedian 8.4x 4.4xmedian 8.4x
EV/EBITDA now vs peer median 505.3xmedian 14.6x -48.6xmedian 14.6x 18.3xmedian 14.6x
P/FCF now vs peer median 15.1xmedian 19.0x -42.3xmedian 19.0x 27.4xmedian 19.0x
P/B now vs peer median 16.0xmedian 2.0x 36.6xmedian 2.0x 6.1xmedian 2.0x
PEG now vs peer median 1.40median 0.43 -2.40median 0.43 0.09median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGILDINSMALNY
Revenue $30.99B $1.52B $5.01B
Gross profit $24.77B $1.28B $3.88B
Operating income -$2.36B -$563.99M $977.59M
Net income -$3.86B -$605.67M $2.65B
Free cash flow $13.78B -$627.58M $806.31M
R&D $6.33B $944.39M $1.56B
EPS (diluted) $-3.09 $-2.77 $19.19
Cash & equivalents $6.44B $396.60M $1.75B
Total debt $26.23B $555.09M $361.53M
Shares (diluted) 1.25B 218.79M 138.04M
Enterprise value $182.67B $21.94B $8.52B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGILDINSMALNY
P/E -54.0x -43.8x 8.3x
P/FCF 15.1x -42.3x 27.4x
P/Operating cash flow 14.4x -44.6x 23.1x
P/S 6.7x 17.5x 4.4x
P/B 16.0x 36.6x 6.1x
P/Tangible book -543.2x 45.2x 6.1x
EV/EBITDA 505.3x -48.6x 18.3x
EV/EBIT -96.7x -46.1x 19.3x
EV/Revenue 7.4x 17.1x 3.8x
EV/FCF 16.6x -41.4x 23.4x
EV/Operating cash flow 15.8x -43.6x 19.7x
PEG (3Y EPS CAGR) 1.40 -2.40 0.09

Growth

14 metrics
MetricGILDINSMALNY
Revenue growth (1Y) 6.5% 240.0% 60.8%
Revenue CAGR (3Y) 4.2% 75.6% 42.7%
Gross profit growth (1Y) 8.2% 274.9% 49.6%
Gross profit CAGR (3Y) 4.7% 79.8% 37.8%
Operating income growth (1Y) -122.5% 51.3% 269.3%
Operating income CAGR (3Y) -31.7% 6.2% 68.2%
Net income growth (1Y) -147.6% 48.8% 2,137%
Net income CAGR (3Y) -38.5% 5.8% 93.1%
EPS growth (1Y) -147.7% 50.5% 2,126%
EPS CAGR (3Y) -38.6% 18.2% 90.8%
Operating cash flow growth (1Y) 49.8% 32.6% 351.6%
Operating cash flow CAGR (3Y) 19.9% -5.4% 685.4%
Free cash flow growth (1Y) 50.4% 30.7% 382.3%
Free cash flow CAGR (3Y) 20.6% -6.2% 141.7%

Profitability

14 metrics
MetricGILDINSMALNY
Gross margin 79.9% 84.4% 77.4%
EBITDA margin 1.5% -35.1% 20.6%
Operating margin -7.6% -37.1% 19.5%
Pretax margin -8.2% -39.4% 15.6%
Net margin -12.5% -39.9% 52.8%
FCF margin 44.5% -41.3% 16.1%
Operating cash flow margin 46.7% -39.2% 19.1%
Return on equity -31.2% -81.9% 106.4%
Return on assets -7.7% -28.1% 38.9%
Return on invested capital -6.1% -41.1% –
Return on capital employed -6.2% -36.0% 20.7%
Asset turnover 0.6x 0.7x 0.7x
Cash conversion (OCF / net income) -3.7x 1.0x 0.4x
Stock comp / revenue 2.9% 11.0% 6.1%

Financial Health

11 metrics
MetricGILDINSMALNY
Debt / assets 51.0% 24.9% 4.5%
Debt / equity 2.0x 0.8x 0.1x
Net debt / EBITDA 43.8x 1.1x -3.1x
Debt / FCF 1.9x -0.9x 0.4x
Liabilities / assets 74.6% 67.4% 54.9%
Equity / assets 25.4% 32.6% 45.1%
Interest coverage -2.3x -5.5x 3.2x
Current ratio 1.4x 2.9x 2.5x
Quick ratio 1.0x 2.4x 2.3x
Cash ratio 0.5x 1.9x 1.7x
Altman Z-score 3.90 7.36 3.78

Shareholder Returns

7 metrics
MetricGILDINSMALNY
Dividend yield 1.9% – –
Net buyback yield 0.5% -0.4% -0.5%
Shareholder yield 2.5% -0.4% -0.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGILDINSMALNY
Forward P/E – – 8.6xFY2026
EPS, next fiscal year $-0.84FY2026 $-1.68FY2026 $19.15FY2026
EPS growth, next FY -110.3%FY2026 – +721.9%FY2026
EPS growth, the year after – – -56.0%
Revenue, next fiscal year $29.15BFY2026 $1.99BFY2026 $5.65BFY2026
Revenue growth, next FY -1.0%FY2026 +227.7%FY2026 +52.2%FY2026
Revenue growth, the year after +18.3% +59.5% +23.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGILDINSMALNY
Held by institutions 89.6% 100.0% 99.7%
Institutions holding 2,293 671 788
Change in shares held, QoQ +5.1% +3.4% +3.8%
Institutions buying 1,113 369 412
Institutions selling 853 230 279
Buyers to sellers 1.30 1.60 1.48

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GILDINSMALNY
GILD 1.00 0.19 0.15
INSM 0.19 1.00 0.02
ALNY 0.15 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GILD, INSM and ALNY?

Gilead Sciences (GILD) is the largest by market capitalisation: Gilead Sciences (GILD) $207.56B, Insmed (INSM) $26.90B, Alnylam Pharmaceuticals (ALNY) $21.33B.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Gilead Sciences (GILD) +6.5%, Insmed (INSM) +240.0%, Alnylam Pharmaceuticals (ALNY) +60.8%.

Which company is more profitable?

Alnylam Pharmaceuticals (ALNY) has the highest net margin (Gilead Sciences (GILD) -12.5%, Insmed (INSM) -39.9%, Alnylam Pharmaceuticals (ALNY) 52.8%). On return on invested capital, Gilead Sciences (GILD) leads (Gilead Sciences (GILD) -6.1%, Insmed (INSM) -41.1%).

Which stock has performed better?

Over the past year Gilead Sciences (GILD) returned the most: Gilead Sciences (GILD) +34.2%, Insmed (INSM) -36.6%, Alnylam Pharmaceuticals (ALNY) -63.6%. Over five years, Insmed (INSM) compounded fastest (Gilead Sciences (GILD) +20.0%/yr, Insmed (INSM) +30.6%/yr, Alnylam Pharmaceuticals (ALNY) -0.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Gilead Sciences (GILD) 27.5%, Insmed (INSM) 62.2%, Alnylam Pharmaceuticals (ALNY) 59.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GILD, INSM and ALNY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Gilead Sciences (GILD) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.